Serum test identifies patients deriving benefit from CPIs 183 5 Figure 2. A–F, Outcomes by test classification for the development cohort. Validation The locked test was applied to samples from validation sets 1 and 2 and the chemotherapy cohort. Validation set 1 had been used in a previous investigation26 and therefore, while it was not used in test development, validation set 1 could not be run blinded to clinical data. The chemotherapy cohort was a subset of a previously analyzed clinical trial comparing chemotherapy and targeted therapy and hence could also not be tested blinded to clinical data. Testing of validation set 2 was completely blinded to all clinical data. Statistical consideration of power to detect the effect sizes observed in the development cohort for each validation set and the chemotherapy cohort is outlined in the supplement.
RkJQdWJsaXNoZXIy MTk4NDMw